Should Intuitive prioritize expanding its Ion robotic-assisted bronchoscopy platform's capabilities or focus on reducing its cost to increase adoption?

Introduction

The trade-off we're examining today is whether Intuitive should prioritize expanding the capabilities of its Ion robotic-assisted bronchoscopy platform or focus on reducing its cost to increase adoption. This decision is crucial for Intuitive's market position and long-term growth in the medical robotics field. I'll analyze this trade-off by considering market dynamics, user needs, technical feasibility, and business impact.

Step 1

Clarifying Questions (3 minutes)

• Context: I'm thinking about the current market penetration of the Ion platform. Could you share what percentage of potential customers have adopted the system so far?

Why it matters: Helps determine if cost or capabilities are the primary barrier to adoption. Expected answer: Low to moderate adoption, around 20-30% of potential market. Impact on approach: Lower adoption would lean towards cost reduction, higher towards capability expansion.

• Business Context: Based on our revenue model, I assume the Ion platform generates recurring revenue through consumables and service contracts. Is this correct, and what's the split between initial sales and recurring revenue?

Why it matters: Influences whether to focus on new customer acquisition or increasing usage among existing customers. Expected answer: 60% recurring revenue, 40% initial sales. Impact on approach: Higher recurring revenue might favor capability expansion to increase usage.

• User Impact: I'm curious about the feedback from current users. What are the top requested features or improvements?

Why it matters: Helps prioritize between cost reduction and specific capability expansions. Expected answer: Mix of requests for new capabilities and concerns about cost. Impact on approach: Would guide which specific capabilities to focus on if expansion is chosen.

• Technical: Regarding capability expansion, are there any significant technical hurdles or regulatory approvals we need to consider?

Why it matters: Affects feasibility and timeline of capability expansion. Expected answer: Some regulatory approvals needed, but no major technical barriers. Impact on approach: Long approval processes might favor short-term focus on cost reduction.

• Resource: What's our current R&D capacity? Are we staffed to pursue both cost reduction and capability expansion simultaneously, or would we need to choose one?

Why it matters: Determines if this is truly an either/or decision or if a balanced approach is possible. Expected answer: Limited resources, need to prioritize one direction. Impact on approach: Would confirm the need to make a clear trade-off decision.